Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,431 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Kidney Disease
Interventions
Immediate release sodium nitrite, Isoquercetin, placebos
Drug · Dietary Supplement · Other
Lead sponsor
Tulane University
Other
Eligibility
21 Years to 74 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Renal Impairment Study for PF-04965842

NCT03660241
Conditions
Renal Impairment
Interventions
PF-04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
Conditions
Chronic Kidney Disease
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Conditions
End-Stage Renal Disease Patients on Hemodialysis
Interventions
Fish oil capsules, matched placebo capsules
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 82 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Atrial Fibrillation, End Stage Renal Disease
Interventions
apixaban, warfarin
Drug
Lead sponsor
Christopher Granger, MD
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
58
States / cities
Huntsville, Alabama • Fresno, California • Long Beach, California + 52 more
Conditions
Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years to 90 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pasedena, Texas
Conditions
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Combination Product
Lead sponsor
Azienda Ospedaliera di Padova
Other
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Conditions
ESRD, Fatigue, Hemodialysis-Induced Symptom
Interventions
Blood Flow Rate Reduction, Control
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years to 89 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Capitola, California • Daly City, California • Gilroy, California + 9 more
Recruiting Not applicable Interventional

Symptom Monitoring in Hemodialysis

NCT05738330
Conditions
End Stage Kidney Disease
Interventions
Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD), Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Renal Insufficiency
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 83 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Conditions
Hyperphosphatemia, End-stage Renal Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
End Stage Renal Disease, ESRD
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Renal Insufficiency, Chronic, Hypertension
Interventions
Texting, mHealth app
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Severe Obesity, Renal Failure
Interventions
Gastric Bypass, Weight Loss Program
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Results available

Evaluation of Patiromer in Heart Failure Patients

NCT00868439
Conditions
Hyperkalemia, Heart Failure
Interventions
patiromer, placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Miami, Florida • Port Charlotte, Florida • Peoria, Illinois + 6 more
Conditions
Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D Repletion in Chronic Kidney Disease

NCT00772772
Conditions
Chronic Kidney Disease
Interventions
Vitamin D3
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Failure, Acute, Renal Replacement Therapy
Interventions
Sodium bicarbonate, Normal saline, Bicarbonate, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Acute Kidney Injury
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Renal Failure, Hemodialysis
Interventions
GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface, Percutaneous Transluminal Angioplasty
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Fresno, California • Inglewood, California + 26 more
Conditions
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
26
States / cities
Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
Completed Not applicable Interventional Results available

Disparities in National Kidney Allocation Policy

NCT02879812
Conditions
Kidney Disorders
Interventions
Performance Feedback Reports, Educational Video for Staff, Educational Video for Patients, Educational Webinar, Standard Care, United Network for Organ Sharing (UNOS) Pamphlet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
56,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Chronic Kidney Disease
Interventions
8 week home-based exercise program
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas